Process Analytical Technology Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

Process Analytical Technology Market Trends and Growth Drivers

Outsourcing of Manufacturing Processes Is Key Industry Trend

• The trend of outsourcing the manufacturing of pharma products continues to burgeon around the world.
• From around USD 17.1 billion, global revenue for biologics CDMO is set to rise to USD 31.8 billion by 2030.
• This is due to various advantages they offer, such as a lower cost of production, lower capital investment, desired quality, time-saving, and flexibility to pharma companies to divert their resources to other areas, such as marketing.
• Additionally, outsourcing allows for easier compliance with the regulations of various bodies.
• For instance, Arvinas Inc. and Pfizer Inc. have a global collaboration to develop and commercialize ARV-471, an investigational oral proteolysis-targeting-chimera (PROTAC) estrogen receptor protein degrader.
• Similarly, Samsung Electronics Co. Ltd. has entered the contract manufacturing space in the biopharmaceutical industry with the diversification of its business in the form of Samsung Biologics.
• Samsung Biologics entered this space to focus on manufacturing generic versions of biologics and offering biomanufacturing outsourcing for Big Pharma.
• Under it, the company will provide end-to-end CDMO services, including cell line development, and clinical drug manufacturing, to support investigational new drug (IND) filings for anti-HIV and anti-SARS-CoV-2 monoclonal antibodies.
• Moreover, the contract manufacturing industry is expected to grow significantly in the future, especially in emerging economies, to meet the surging need for pharma products, thereby supporting the demand for PAT.

Growing Adherence to QbD Principles Drives Market

• The QbD principles given by Joseph M. Juran, a quality expert and management consultant, are used to advance product and process quality in various industries.
• These principles emphasize that quality can be planned and that most quality problems are associated with the way in which the quality was planned.
• QbD is an emerging practice to ensure safe, effective drug supply to consumers and significantly improve manufacturing quality and performance.
• The principles have been adopted by the USFDA for the discovery, development, and manufacturing of drugs.
• In 2002, at the USFDA’s Office of New Drug Quality Assessment (ONDQA), a new risk-based pharmaceutical quality assessment system (PQAS) was recognized based on the application of process and product understanding.
• Additionally, a pilot program was implemented to allow pharma manufacturers to submit information for a new drug application (NDA) demonstrating the use of these principles, process understanding, and product knowledge.
• In January 2011, the USFDA released a process validation guidance that records the requirement of organizations to continue benefiting from the information gained and continually improving the process lifecycle, by making revisions to guarantee that the root causes of manufacturing glitches are rapidly corrected.
• Moreover, in January 2013, the USFDA began the process to implement the QbD principles into their Abbreviated New Drug Applications (ANDA), Module 3 Quality 3.2.P.2 Pharmaceutical Development, for generic drug manufacturers.
• The aim is to propose a control strategy that includes input material attributes and process parameters identified as potentially high-risk variables during the initial risk assessment.
• Additionally, it includes in-process and finished product specifications.
• The process is monitored during the lifecycle of the product, and the additional knowledge gained is utilized to make adjustments to the control strategy, as appropriate.
• With such regulations around the world, adherence to the QbD principles is increasing among pharma and biopharma companies, thereby promoting the implementation of advanced PAT.

Process Analytical Technology Market Analysis

Technique Analysis

The spectroscopy category held the largest market share, of 50%, in 2024, and it is projected to attain the fastest growth during the forecast period. This is attributed to the increasing pharmaceutical and biopharmaceutical R&D activities and technological advancements resulting in process optimization. Moreover, spectroscopy helps in the determination of the atomic structure of a sample and the molecular structure of the muscle, monitoring of dissolved oxygen content in freshwater and marine ecosystems, studying of the emission lines of distant galaxies, alteration of drug structure to improve effectiveness, characterization of proteins, space exploration, and respiratory gas analysis in hospitals.

In addition, molecular spectroscopy has been the most widely used spectroscopy technique. The category is also expected to experience considerable growth during the forecast period, due to its wide application and increasing demand in the pharmaceutical and biopharmaceutical industries.

These techniques are covered:

• Spectroscopy (Largest and Fastest-Growing Category)
  • Molecular
  • Atomic
  • Mass
• Chromatography
  • Liquid chromatography (LC)
  • Gas chromatography (GC)
• Capillary Electrophoresis
• Particle Size Analysis
• Others

End User Analysis

Pharmaceutical manufacturers accounted for the largest revenue share in 2024. This is because PAT acquires an important role in the process development and scaling up the asymmetric syntheses of chiral molecules, including active pharmaceutical ingredients, in the pharmaceutical industry.

The biopharmaceutical manufacturers category is expected to witness the fastest growth during the forecast period, with 20% CAGR. This is owing to the growing biotechnology industry and the rising demand for biochemical analysis due to the approval and launch of various biologic drugs.

These end users are covered:

• Pharmaceutical Manufacturers (Largest Category)
• Biopharmaceutical Manufacturers (Fastest-Growing Category)
• Contract Research and Manufacturing Organizations
• Others

Measurement Analysis

The in-line measurement led the market in 2024, with 40% revenue share, and it is expected to attain the same position in the coming years. With batch production being widely employed in the pharmaceutical industry, in-line measurements are the most-widely utilized measurements as part of PAT projects.

The on-line measurement category at the highest CAGR during the forecast period due to the low turnaround time and consistency in results obtained by on-line analysis. Moreover, with the advancements in PATs, on-line measurements are being adopted at a high rate in developed countries.

These measurements are covered:

• In-Line (Largest Category)
• At-Line
• On-Line (Fastest-Growing Category)
• Off-Line

Offering Analysis

The products category dominated the market in 2024 with a share of 70%. Products in the global PAT market include analyzers, sensors and probes, and samplers. The increasing drug discovery and development activities and stringent regulations for drug safety are stimulating the demand for PAT products.

The services category is expected to register the faster growth, at a CAGR of 20.5%, during the forecast period due to the increasing demand for chemometrics and statistics data processing services.

These offerings are covered:

• Products (Larger Category)
  • Analyzers
  • Sensors and probes
  • Samplers
• Services (Faster-Growing Category)

Process Analytical Technology Market Geographical Outlook

North America held the largest share in the global PAT market in 2024, of 40%. The market in these countries is expected to grow on account of the rising R&D expenditure by pharmaceutical and biopharmaceutical companies, surging investments by governments, increasing focus on quality and manufacturing efficiency improvement, and growing adherence to QbD principles by companies operating in these countries.

The presence of the majority of global PAT manufacturers and regulatory authorities that have stipulated strict quality standards to comply with for pharmaceutical companies, growing biotechnology industry and consequently increasing use of analytical technologies, and high R&D expenditure by pharmaceutical companies in the region are some of the key factors driving the market in the region. The presence of the major players has led to a high sale of such solutions to the pharmaceutical and chemical industries of the region.

The U.S. holds the larger share in the North American PAT market, mainly attributable to the larger size of the pharmaceutical industry in the country, high R&D expenditure, and presence of various large players providing PATs in the country. Moreover, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group represents the leading biopharmaceutical research companies in the U.S. In 2023, the R&D expenditure of its member companies reached around USD 96 billion.

The APAC PAT market is expected to witness the highest CAGR, of 22%, during the forecast period. This can be ascribed to the presence of various USFDA-approved pharmaceutical companies, the rapid growth in the biotechnology industry along with the increasing use of analytical technologies, high R&D expenditure, a surge in the prevalence of various diseases that leads to a rise in the consumption of pharmaceutical and biologic drugs, and the increase in healthcare expenditure in the region.

For instance, according to the World Bank, healthcare expenditure as a percentage of the GDP in China increased from 5.17% in 2018 to 5.35% in 2019, 7.08% in 2022, and 7.19% in 2023. Similarly, India’s healthcare expenditure grew at a CAGR of 15.8% between FY 2018 and FY 2024, reaching INR 5.85 lakh crore, as per the Press Information Bureau.

Additionally, it is projected that the growing interest of international organizations in emerging markets and the expansion of contract research and manufacturing companies in the region would create new growth prospects for industry players.

These regions and countries are covered:

• North America (Largest Regional Market)
  • U.S. (Larger and Faster-Growing Country Market)
  • Canada
• Europe
  • Germany (Largest Country Market)
  • U.K.
  • France (Fastest-Growing Country Market)
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China (Largest Country Market)
  • Japan
  • India (Fastest-Growing Country Market)
  • South Korea
  • Australia
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest and Fastest-Growing Country Market)
  • Mexico
  • Rest of LATAM
• Middle East & Africa (MEA)
  • Saudi Arabia (Largest Country Market)
  • U.A.E. (Fastest-Growing Country Market)
  • South Africa
  • Rest of MEA

Process Analytical Technology Market Share

• The market is fragmented as the offerings are diverse, including both products and services.
• Moreover, the products include both common stuff, such as probes and samplers as well as complex analyzers.
• Additionally, even more companies develop software for such machines; the increasing penetration of AI, big data analytics, and other cutting-edge technologies widens the opportunity for players.
• The exact setup may need to be modified for application in different industries, further fragmenting the market.
• The availability of numerous techniques also means that different companies possess varying expertise.

Process Analytical Technology Market News

• In January 2025, Shimadzu Corporation introduced the upgraded model of its Brevis GC-2050 gas chromatography system, by including all major kinds of detectors, inlets, mass spectrometers, and pre-treatment devices.
• In August 2024, Mettler-Toledo International Inc. launched the InSUS H30i reusable sensor head and InSUS 310i disposable pH sensor. Featuring noise and EMI resistance and the Intelligent Sensor Management technology, the combined solution enables more-accurate measurements of the pH, easy management of the sensors, and documentation of the entire analytical process.
• In April 2024, Bruker Corporation launched the Ascend Evo 600, a new NMR magnet with a power of 14.1 Teslas and a standard bore of 54 millimeters. The magnet is offered for biopharma drug discovery & development, academic basic and clinical research, and process analytical technologies.
• In April 2024, PerkinElmer Inc. launched its NexION 1100 ICP-MS mass spectrometer for trace element analysis.